<p>SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Published:2019-07 Issue: Volume:Volume 12 Page:1001-1012
ISSN:1178-7007
Container-title:Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
language:en
Short-container-title:DMSO

Author:

Gharaibeh Naser Eddin^ORCID,Rahhal Marie-Noel^ORCID,Rahimi Leili,Ismail-Beigi Faramarz

Publisher

Informa UK Limited

Subject

Pharmacology,Internal Medicine

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adipose tissue in cortisol excess: What Cushing’s syndrome can teach us?;Biochemical Pharmacology;2024-05

2. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus;PLOS ONE;2023-11-22

3. The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?;Journal of Cardiovascular Development and Disease;2023-11-16

4. RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor;Biomedicine & Pharmacotherapy;2023-10

5. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials;African Health Sciences;2022-10-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP